We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
at 1408 share price 66-70 some one bought 37000 @74 shares price did not move presumably no stock in market the quote should have gone better
Nice trade of 50000@72 Friday afternoon bodes well for Ixico today, there has been low volume lately
Ixico share price has been very steady.i t has a better tone last few days with no sellers it seems looks like they are going higher after those excellent figures
How many companies have produced such strong figures and positive statement in current climate . If it was not for Covid 19 the recommendation would be Strong Buy
Generally good - the cash statement is a little worrying - reduction in cash overall despite being profitable - quite a lot of investment in plant etc, also £101k in staff intangibles being capitalised. Some of this may be buying equipment to allow staff to work remotely through CV19 period perhaps.
General admin costs down £300K BUT R&D and Sales costs up considerably..........
So I think the results are a little less strong when this cash outflow is considered.
Yes already reported
Order book of £15.3 million at 31 March 2020, increased to over £22 million in April 2020 on signing contracts post-period end;
looking at the last prediction everything looks good.
Trading update for H1 2020
33% revenue growth; £4.6m revenues for the 6 months to 31 March 2020
Strong closing cash balance of £6.7m
£15.3m order book at 31 March strengthened further to £22.5m as at 20 April 2020
I look forward to Ixico interim results tomorrow .Although under today’s environment I don’t expect any new contracts it would be a nice suprise
Great results
from RNS: "Clinical trial operations have been affected by the ongoing travel restrictions and social distancing policies put in place by governments across the world and several pharmaceutical companies have already announced suspensions or the slowing down of clinical trials. COVID-19 could also lead to clinical sites being quarantined or closed down, as well as further restrictions on travel and interruptions to the supply of investigational product to patients."
no news is a good news , looks like IXI is in position to carry on as normal.
BUT very little information on the impact (positive or negative) of Covid-19 on the business............"head winds"
Ii is a disgrace this site is not showing RNS on Ixico when it was announced, Considering the difficult times we live in this is an excellent update,This is an extremely exciting company well run with skilled and dedicated staff
IXICO plc - IXI £10.5m contract win, update on trading & COVID-19
07:00 14-Apr-2020 RNS 0.00% View chart
Can someone explain the last mark 45000 @48 it seem a very low sale price for only £21/- stock looks like someone has dealt very badly
Does anyone know if Ixico artificial intelligence could help in the fight against Covid19
i agree mate this is a bargain at this price, IXICO products are in demand and the future looks even better.
On 15 Oct 2019 Cenkos reiterated there buy recomendation @55p since then they have had very positive financial results and more contract announcements.they closed on friday at 55.5p The market has been badly spooked creating sellers on 27 December Ixico shatre price eas 95.5 . The fundamentals have not change
As far as I know nothing changed bought some more yesterday
Have not seen any negative news is this just profit taking triggering sells or has there been reasons relating to Ixico?
Many thanks
The trade at 10.30 of 13000 @60.5 is a buy not a sale it was me big fall today caused by market fear.
Thank you Volcano for the info. This has all the makings of a great company if the opportunities are properly handled. A huge need here as the developed world ages.
demand will rise as people live longer .
IXICO plc is a brain health company. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose dementia and detect the underlying causes. mehealth is an online software for clinicians at the point-of-care to support decision making and improve the monitoring and treatment of patients. MyBrainBook is a digital platform to improve the quality of life and service delivery for people living with dementia and their supporters. TrialTracker is a Web-based system that allows users to track their imaging-based research study or clinical trial in real time. It is also collaborating with partners to develop companion digital health products.